Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

Development of Both Methotrexate and Mitomycin C Loaded PEGylated Chitosan Nanoparticles for Targeted Drug Codelivery and Synergistic Anticancer Effect

(2014) Mengmeng Jia et al.   ACS Applied Materials & Interfaces

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

(2014) Kristi McIntyre et al.   BREAST CANCER RESEARCH AND TREATMENT

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane

(2013) Shigehira Saji   BIODRUGS

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

(2011) K. Aogi et al.   ANNALS OF ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study

(2010) Kais Aldabbagh et al.   Breast Cancer

Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

(2009) Masahiko Tanabe et al.   Breast Cancer

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine

(2008) Yoshinori Ito et al.   Breast Cancer